Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVanderbilt University Medical Center
About this trial
The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adults aged 18 or older
Disqualifiers
Pregnant
Prisoner or in police custody
Uncontrolled hyperglycemia/diabetes
Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
Trial design
Design model
Single group
Treatments tested in this trial
13C6-Glucose
DrugCompounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion
Treatment groups
12 Participants
are divided into 1 treatment groupGroup A: 13C6-GlucoseOther 1 intervention
Trial outcomes
Primary outcomes
1
13C6-glucose uptake in immune cells
Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.
Time frame
Up to 4 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov